Assessment of the Role and Timing of Glaucoma Surgery in Boston Keratoprosthesis Type 1 Patients.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
03 2022
Historique:
received: 10 03 2021
revised: 06 09 2021
accepted: 07 09 2021
pubmed: 21 9 2021
medline: 8 4 2022
entrez: 20 9 2021
Statut: ppublish

Résumé

To determine the role and optimal timing of glaucoma surgery in relation to Boston keratoprosthesis type 1 (KPro) implantation. Retrospective, comparative, nonrandomized clinical study. Single-center study of a total of 100 eyes (100 patients) implanted with a KPro between 2008 and 2017, and diagnosed with glaucoma before or after KPro. Patients were separated into 2 groups: those with preexisting glaucoma and those who developed de novo glaucoma after KPro. Groups were then divided based on whether patients were medically or surgically managed. Glaucoma surgery included glaucoma drainage device (GDD) implantation, trabeculectomy, and cyclophotocoagulation (CPC). Primary outcomes included best-corrected visual acuity (BCVA), glaucoma progression, and complications. Differences in outcomes were compared using parametric and nonparametric tests, as well as log-rank test to compare time-to-outcome events. Among 72 eyes with preexisting glaucoma, 27 (38%) had glaucoma surgery before KPro (18 GDD), whereas 45 (62%) were medically managed only. Among the latter, 19 (42%) needed glaucoma surgery post-KPro (16 GDD). Among 28 eyes with de novo glaucoma, 12 (43%) had glaucoma surgery post-KPro (9 GDD). For eyes with preexisting glaucoma, glaucoma progression was greater with glaucoma surgery performed post-KPro (100%) compared with pre-KPro (74%, P = .016) and to medical management (54%, P = .002). No increase in complications were observed with glaucoma surgery compared to medications only (P > .05), whereas fewer eyes maintained a BCVA of 20/200 or better over time with medical management (P = .013). Eyes with de novo glaucoma had similar progression, BCVA, and complications between medical and surgical care (P > .05). Glaucoma surgery should be performed before or at the same time as KPro implantation in eyes with preexisting glaucoma. Complication rates are not increased when glaucoma surgery is performed in KPro eyes with either preexisting or de novo glaucoma. To ensure optimal glaucoma control, glaucoma surgery should be performed as early as possible in KPro eyes with good visual potential.

Identifiants

pubmed: 34543660
pii: S0002-9394(21)00460-8
doi: 10.1016/j.ajo.2021.09.005
pii:
doi:

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-257

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Dominique Geoffrion (D)

From the Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM) (D.G., S.I.H., M.M., R.D., Y.A., M.H.-D.), Montreal, Quebec, Canada; Department of Experimental Surgery, Faculty of Medicine, McGill University (D.G.), Montreal, Quebec, Canada.

Salima I Hassanaly (SI)

Department of Ophthalmology & Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago (S.I.H.), Chicago, Illinois, USA.

Michael Marchand (M)

From the Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM) (D.G., S.I.H., M.M., R.D., Y.A., M.H.-D.), Montreal, Quebec, Canada.

Roy Daoud (R)

From the Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM) (D.G., S.I.H., M.M., R.D., Y.A., M.H.-D.), Montreal, Quebec, Canada.

Younes Agoumi (Y)

From the Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM) (D.G., S.I.H., M.M., R.D., Y.A., M.H.-D.), Montreal, Quebec, Canada.

Mona Harissi-Dagher (M)

From the Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM) (D.G., S.I.H., M.M., R.D., Y.A., M.H.-D.), Montreal, Quebec, Canada. Electronic address: monadagher@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH